BRPI0811589B8 - composição farmacêutica, e, usos de uma composição farmacêutica - Google Patents
composição farmacêutica, e, usos de uma composição farmacêuticaInfo
- Publication number
- BRPI0811589B8 BRPI0811589B8 BRPI0811589A BRPI0811589A BRPI0811589B8 BR PI0811589 B8 BRPI0811589 B8 BR PI0811589B8 BR PI0811589 A BRPI0811589 A BR PI0811589A BR PI0811589 A BRPI0811589 A BR PI0811589A BR PI0811589 B8 BRPI0811589 B8 BR PI0811589B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pal
- variants
- compositions
- prokaryotic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122018072594A BR122018072594B8 (pt) | 2007-08-17 | 2008-08-15 | uso de uma composição farmacêutica |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 | |
| US61/066,125 | 2007-08-17 | ||
| PCT/US2008/009765 WO2009025760A2 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0811589A2 BRPI0811589A2 (pt) | 2014-10-29 |
| BRPI0811589B1 BRPI0811589B1 (pt) | 2020-05-12 |
| BRPI0811589B8 true BRPI0811589B8 (pt) | 2021-05-25 |
Family
ID=40363135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811589A BRPI0811589B8 (pt) | 2007-08-17 | 2008-08-15 | composição farmacêutica, e, usos de uma composição farmacêutica |
| BR122018072594A BR122018072594B8 (pt) | 2007-08-17 | 2008-08-15 | uso de uma composição farmacêutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122018072594A BR122018072594B8 (pt) | 2007-08-17 | 2008-08-15 | uso de uma composição farmacêutica |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7560263B2 (enExample) |
| EP (1) | EP2175875B1 (enExample) |
| JP (1) | JP5584120B2 (enExample) |
| CN (1) | CN101803492B (enExample) |
| AR (2) | AR067972A1 (enExample) |
| AU (1) | AU2008289549B2 (enExample) |
| BR (2) | BRPI0811589B8 (enExample) |
| CA (1) | CA2687028C (enExample) |
| CL (1) | CL2008002390A1 (enExample) |
| CY (1) | CY1118222T1 (enExample) |
| DK (1) | DK2175875T3 (enExample) |
| ES (1) | ES2602618T3 (enExample) |
| HR (1) | HRP20161474T1 (enExample) |
| HU (1) | HUE029510T4 (enExample) |
| LT (1) | LT2175875T (enExample) |
| MX (1) | MX2009012261A (enExample) |
| PE (1) | PE20090605A1 (enExample) |
| PL (1) | PL2175875T3 (enExample) |
| PT (1) | PT2175875T (enExample) |
| RU (2) | RU2553343C2 (enExample) |
| SI (1) | SI2175875T1 (enExample) |
| TW (1) | TWI418787B (enExample) |
| WO (1) | WO2009025760A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7560263B2 (en) | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| PL3025728T3 (pl) * | 2010-02-04 | 2018-12-31 | Biomarin Pharmaceutical Inc. | Sposób oczyszczania wariantów prokariotycznej amoniakoliazy fenyloalaninowej |
| WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US20150246083A1 (en) * | 2012-07-27 | 2015-09-03 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| CN105324483B (zh) | 2013-04-18 | 2018-11-30 | 科德克希思公司 | 工程化苯丙氨酸解氨酶多肽 |
| JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | 合成膜−レシーバー複合体 |
| RU2736495C2 (ru) | 2014-04-01 | 2020-11-17 | Рубиус Терапьютикс, Инк. | Способ и композиции для иммуномодуляции |
| DK3145536T3 (da) | 2014-04-16 | 2022-01-03 | Codexis Inc | Modificeret tyrosinammoniaklyase |
| WO2015165374A1 (en) | 2014-04-29 | 2015-11-05 | Bio-Cancer Treatment International Limited | Methods and compositions for modulating the immune system with arginase i |
| US10752923B2 (en) | 2014-07-14 | 2020-08-25 | Cysbio Aps | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| US20170360900A1 (en) | 2014-12-22 | 2017-12-21 | Codexis, Inc. | Human alpha-galactosidase variants |
| US11584780B2 (en) | 2016-07-26 | 2023-02-21 | Biomarin Pharmaceutical Inc. | Adeno-associated virus capsid proteins |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| NZ755628A (en) | 2017-02-13 | 2023-09-29 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| WO2019217513A2 (en) | 2018-05-09 | 2019-11-14 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| CA3102968A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| BR112021011750A2 (pt) | 2018-12-20 | 2021-08-31 | Codexis, Inc. | Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições |
| AU2020220398B2 (en) | 2019-02-14 | 2025-02-27 | Som Innovation Biotech, S.A. | Triamterene or nolatrexed for use in the treatment of phenylketonuria |
| TW202126335A (zh) * | 2019-08-07 | 2021-07-16 | 美商樂天醫藥生技股份有限公司 | 西妥昔單抗(cetuximab)-ir700結合物組合物 |
| EP4501403A3 (en) | 2019-08-30 | 2025-05-14 | Société des Produits Nestlé S.A. | Engineered lipase variants |
| AU2020408066A1 (en) | 2019-12-20 | 2022-06-30 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| KR20220137057A (ko) | 2020-02-04 | 2022-10-11 | 코덱시스, 인코포레이티드 | 조작된 류신 데카르복실라제 |
| AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
| WO2022047262A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
| CA3191900A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| WO2022245924A1 (en) | 2021-05-19 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
| EP4341395A4 (en) | 2021-05-21 | 2025-07-23 | Syntis Bio Inc | MODIFIED METHIONINE GAMMA LYASE VARIANTS |
| US12502421B2 (en) | 2021-11-01 | 2025-12-23 | Syntis Bio, Inc. | Engineered leucine decarboxylases |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| TW202521161A (zh) | 2023-11-17 | 2025-06-01 | 美商拜奧馬林製藥公司 | 苯丙胺酸解氨酶與ｐｏｅｇｍａ之結合物及其使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| ATE440615T1 (de) | 1992-11-19 | 2009-09-15 | Anticancer Inc | Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie |
| CA2149922C (en) | 1992-12-04 | 2007-05-15 | Thomas W. Macallister | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| DK75593D0 (enExample) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| DE69635026T2 (de) | 1995-09-21 | 2006-05-24 | Genentech Inc., San Francisco | Varianten des menschlichen wachstumshormons |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| CA2328614C (en) | 1999-02-12 | 2012-06-26 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280924A2 (en) | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) * | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| EP1476563B1 (en) | 2002-02-26 | 2008-09-17 | E.I. Du Pont De Nemours And Company | Method for the recombination of genetic elements |
| WO2004044169A2 (en) | 2002-11-14 | 2004-05-27 | The Scripps Research Institute | Crystalline form of fatty acid amine hydrolase (faah) |
| US7553653B2 (en) | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| US20090038023A1 (en) | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7560263B2 (en) | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en not_active Ceased
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0811589B8 (pt) | composição farmacêutica, e, usos de uma composição farmacêutica | |
| BRPI0811267B8 (pt) | variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku) | |
| CA2782444C (en) | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof | |
| MX2009001203A (es) | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| ECSP11011044A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| MD4496B1 (ro) | Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral | |
| BR112012014066A2 (pt) | preparações de combinações com exossomos e corticosteróide | |
| PE20061107A1 (es) | Composiciones de tigeciclina y metodos para su preparacion | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BR112015011244A8 (pt) | análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| WO2008075369A3 (en) | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| GB0625648D0 (en) | Compounds | |
| IN2012DN00639A (enExample) | ||
| MX2009009153A (es) | Pirano-pirazol-aminas. | |
| BR112012022255A2 (pt) | composição farmaceuticaestabilizada | |
| BR112013026698A2 (pt) | formulações do tipo tópica compreendendo depsipeptídeo cíclico | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| ATE552734T1 (de) | Verfahren zur herstellung des interleukin- produktionsreglers | |
| PE20121553A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria | |
| WO2014115084A3 (en) | Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |